BDBM50371265 HYDROCORTISONE CYPIONATE Cortef Hydrocortisone Cyclopentylpropionate
CHEBI:31677 BDBM50016931 HYDROCORTISONE HEMISUCCINATE NSC-7576 Hydrocortisone Succinate
Sodium; butyrate Sodium butyrate CHEMBL62381 butyrate butanoate BDBM50079401
Rutin butyrate BDBM237185
3-OH-butyrate beta-hydroxy-n-butyrate beta-hydroxybutanoate 3-hydroxybutyrate BDBM50270275 3-hydroxybutanoate 3-OH butyrate
Cleviprex Clevidipine Clevidipine butyrate BDBM50088387
ethylacetate CH3-[CH2]2-COO(-) butanoic acid, ion(1-) butyrate n-butyrate 1-butyrate butanoate butanate 1-butanoate BDBM50240451 n-butanoate propylformate 1-propanecarboxylate propanecarboxylate
butanoic acid, 4 butanoic acid BDBM26109 Butyrate
BDBM50344957 CHEMBL1162497 3-hydroxy-butyrate (S)-3-hydroxybutanoate (3S)-3-HYDROXYBUTANOIC ACID
Sodium; 4-{2-[(4-chloro-benzenesulfonylamino)-methyl]-indan-5-yl}-butyrate BDBM50075079 CHEMBL334501
Hemsol-Hc BDBM50474607 Micort-Hc Hydrocortisone 21-acetate Neo-Cortef CHEBI:17609 NSC-741 Gppe Eye Crm Dricort Cortucid Hepacort Plus Orabase Hca Epifoam Genticin HC Barquinol HC Gentisone HC Framycort Hc45 Hydrocort Hydrocortone Gppe Foam Aero Chloromycetin Hydrocort Lanacort Hydrocortisone Acetate Cortifoam Gppe Ear Susp Cortril Fucidin H Cortef Acetate Colifoam Hydrocal
CHEMBL305933 Sodium; 4-[(1R,3S)-1-hydroxy-3-((E)-3-hydroxy-oct-1-enyl)-cyclohexyl]-butyrate BDBM50287891
delphinate isopentanoate 3-methylbutanoate beta-methylbutyrate isopropylacetate isovalerate BDBM50269962 3-methyl-n-butyrate 3-methylbutyrate CHEMBL1762642 isovalerianate
BDBM50045378 CHEMBL88912 (20S)-Sodium; 2-hydroxy-2-(8-hydroxymethyl-9-oxo-9,11-dihydro-indolizino[1,2-b]quinolin-7-yl)-butyrate (20RS)-Sodium; 2-hydroxy-2-(8-hydroxymethyl-9-oxo-9,11-dihydro-indolizino[1,2-b]quinolin-7-yl)-butyrate
BDBM50087301 CHEMBL290418 Sodium; 4-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-ylmethoxy)-butyrate H2O
BDBM50124324 CHEMBL170189 Sodium; 4-{3-[2-amino-3-cyano-6-(2-hydroxy-phenyl)-pyridin-4-yl]-phenylcarbamoyl}-butyrate
BDBM50124334 Sodium; 4-[3-(2-amino-3-cyano-6-phenyl-pyridin-4-yl)-phenylcarbamoyl]-4-hydroxy-butyrate CHEMBL444345
BDBM50280709 Sodium; 2-[1-[3-(7-chloro-quinolin-2-ylmethoxy)-phenyl]-3-(2-methanesulfonyl-phenyl)-propylsulfanylmethyl]-butyrate CHEMBL15344
CHEMBL15120 BDBM50280686 Sodium; 2-{3-(2-carbamoyl-phenyl)-1-[3-(7-chloro-quinolin-2-ylmethoxy)-phenyl]-propylsulfanylmethyl}-butyrate
CHEMBL170406 Sodium; 4-{4-[2-amino-3-cyano-6-(2-hydroxy-phenyl)-pyridin-4-yl]-phenylcarbamoyl}-butyrate BDBM50124310
CHEMBL280310 BDBM50280687 Sodium; 2-[1-[3-(7-chloro-quinolin-2-ylmethoxy)-phenyl]-3-(2-ethylcarbamoyl-phenyl)-propylsulfanylmethyl]-butyrate
Sodium; 2-{3-(2-carboxy-phenyl)-1-[3-(7-chloro-quinolin-2-ylmethoxy)-phenyl]-propylsulfanylmethyl}-butyrate BDBM50280697 CHEMBL280260
BDBM50264744 CHEMBL487088 (S)-1-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-3-phenylpropan-2-yl butyrate
BDBM50124319 Sodium; 4-{3-[2-amino-3-cyano-6-(2-hydroxy-phenyl)-pyridin-4-yl]-phenylcarbamoyl}-4-hydroxy-butyrate CHEMBL434691
CHEMBL10955 BDBM50076797 Lithium; (S)-2-{[2'-methyl-5-(5-phenyl-furan-2-ylmethoxymethyl)-biphenyl-2-carbonyl]-amino}-4-methylsulfanyl-butyrate
CHEMBL1630260 BDBM50332811 (8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[alpha]phenanthren-4-yl butyrate
CHEMBL170355 Sodium; 4-{3-[2-amino-3-cyano-6-(2-methoxy-phenyl)-pyridin-4-yl]-phenylcarbamoyl}-4-hydroxy-butyrate BDBM50124332
CHEMBL424000 Sodium; 4-{3-[2-amino-3-cyano-6-(4-hydroxy-phenyl)-pyridin-4-yl]-phenylcarbamoyl}-4-hydroxy-butyrate BDBM50124318
Sodium; 2-[1-{3-[2-(7-chloro-quinolin-2-yl)-ethyl]-phenyl}-3-(2-cyano-phenyl)-propylsulfanylmethyl]-butyrate BDBM50280708 CHEMBL416161
Sodium; 2-[1-{3-[2-(7-chloro-quinolin-2-yl)-ethyl]-phenyl}-3-(2-ethoxycarbonylamino-phenyl)-propylsulfanylmethyl]-butyrate BDBM50280695 CHEMBL279630
Sodium; 2-{1-[3-(7-chloro-quinolin-2-ylmethoxy)-phenyl]-3-[2-(toluene-2-sulfonylaminocarbonyl)-phenyl]-propylsulfanylmethyl}-butyrate BDBM50280688 CHEMBL429975
Sodium; 4-{4-[3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-propylsulfanyl]-phenyl}-4-hydroxy-3-methyl-butyrate BDBM50025103 CHEMBL41301
BDBM50280703 CHEMBL278210 Sodium; 2-{1-[3-(7-chloro-quinolin-2-ylmethoxy)-phenyl]-3-[2-(1H-tetrazol-5-yl)-phenyl]-propylsulfanylmethyl}-butyrate
Lithium; (S)-4-methylsulfanyl-2-{[2'-methyl-5-(5-p-tolyl-furan-2-ylmethoxymethyl)-biphenyl-2-carbonyl]-amino}-butyrate CHEMBL10990 BDBM50076791
BDBM50045366 (20RS)-Sodium; 2-(1-amino-8-hydroxymethyl-9-oxo-9,11-dihydro-indolizino[1,2-b]quinolin-7-yl)-2-hydroxy-butyrate CHEMBL314025
BDBM50076790 CHEMBL10902 Lithium; (S)-2-{[2'-methyl-5-(5-pyridin-3-yl-furan-2-ylmethoxymethyl)-biphenyl-2-carbonyl]-amino}-4-methylsulfanyl-butyrate
BDBM50076800 CHEMBL430307 Lithium; (S)-2-({5-[5-(4-acetyl-phenyl)-furan-2-ylmethoxymethyl]-2'-methyl-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyrate
BDBM50076801 CHEMBL430096 Lithium; (S)-2-({2'-methyl-5-[5-(3-nitro-phenyl)-furan-2-ylmethoxymethyl]-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyrate
BDBM50076802 Lithium; (S)-2-{[2'-methyl-5-(5-pyridin-4-yl-furan-2-ylmethoxymethyl)-biphenyl-2-carbonyl]-amino}-4-methylsulfanyl-butyrate CHEMBL10912
BDBM50076803 Lithium; (S)-2-({5-[5-(2-fluoro-phenyl)-furan-2-ylmethoxymethyl]-2'-methyl-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyrate CHEMBL10970
BDBM50076804 Lithium; (S)-4-methylsulfanyl-2-({2'-methyl-5-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethoxymethyl]-biphenyl-2-carbonyl}-amino)-butyrate CHEMBL273507
BDBM50076809 CHEMBL417606 Lithium; (S)-2-({5-[5-(4-formyl-phenyl)-furan-2-ylmethoxymethyl]-2'-methyl-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyrate
BDBM50076813 CHEMBL10687 Lithium; (S)-2-({5-[5-(2-methoxy-phenyl)-furan-2-ylmethoxymethyl]-2'-methyl-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyrate
CHEMBL10877 BDBM50076811 Lithium; (S)-2-({5-[5-(4-chloro-phenyl)-furan-2-ylmethoxymethyl]-2'-methyl-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyrate
CHEMBL11195 BDBM50076788 Lithium; (S)-2-({5-[5-(3-fluoro-phenyl)-furan-2-ylmethoxymethyl]-2'-methyl-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyrate
CHEMBL171587 Sodium; 4-{3-[2-amino-3-cyano-6-(2-hydroxy-phenyl)-5-methyl-pyridin-4-yl]-phenylcarbamoyl}-4-hydroxy-butyrate BDBM50124328
CHEMBL173747 Sodium; 4-{3-[2-amino-3-cyano-6-(2-hydroxy-5-methoxy-phenyl)-pyridin-4-yl]-phenylcarbamoyl}-4-hydroxy-butyrate BDBM50124314
CHEMBL273265 BDBM50076806 Lithium; (S)-2-({5-[5-(4-methoxy-phenyl)-furan-2-ylmethoxymethyl]-2'-methyl-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyrate
CHEMBL273697 Lithium; (S)-2-({5-[5-(4-fluoro-phenyl)-furan-2-ylmethoxymethyl]-2'-methyl-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyrate BDBM50076798
CHEMBL273721 Lithium; (S)-2-({5-[5-(3-methoxy-phenyl)-furan-2-ylmethoxymethyl]-2'-methyl-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyrate BDBM50076807
CHEMBL276602 BDBM50076794 Lithium; (S)-2-({5-[5-(4-isopropyl-phenyl)-furan-2-ylmethoxymethyl]-2'-methyl-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyrate
CHEMBL428001 BDBM50076810 Lithium; (S)-4-methylsulfanyl-2-({2'-methyl-5-[5-(4-trifluoromethyl-phenyl)-furan-2-ylmethoxymethyl]-biphenyl-2-carbonyl}-amino)-butyrate
Lithium; (S)-2-({2'-methyl-5-[5-(4-methylsulfanyl-phenyl)-furan-2-ylmethoxymethyl]-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyrate CHEMBL11003 BDBM50076793
Lithium; (S)-2-({5-[5-(4-dimethylamino-phenyl)-furan-2-ylmethoxymethyl]-2'-methyl-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyrate CHEMBL11210 BDBM50076795
Lithium; (S)-2-{[2'-methyl-5-(5-pyridin-2-yl-furan-2-ylmethoxymethyl)-biphenyl-2-carbonyl]-amino}-4-methylsulfanyl-butyrate BDBM50076808 CHEMBL10762
Lithium; (S)-4-methylsulfanyl-2-({2'-methyl-5-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethoxymethyl]-biphenyl-2-carbonyl}-amino)-butyrate BDBM50076789 CHEMBL274672
Sodium; 4-{3-[2-amino-3-cyano-6-(2-hydroxy-6-methoxy-phenyl)-pyridin-4-yl]-phenylcarbamoyl}-4-hydroxy-butyrate BDBM50124315 CHEMBL173111
Sodium; 4-{3-[2-amino-3-cyano-6-(2-hydroxy-6-methyl-phenyl)-pyridin-4-yl]-phenylcarbamoyl}-4-hydroxy-butyrate BDBM50124333 CHEMBL171680
Sodium; 4-{3-[2-amino-3-cyano-6-(5-fluoro-2-hydroxy-phenyl)-pyridin-4-yl]-phenylcarbamoyl}-4-hydroxy-butyrate CHEMBL366730 BDBM50124317
Sodium; 4-{3-[2-amino-6-(5-chloro-2-hydroxy-phenyl)-3-cyano-pyridin-4-yl]-phenylcarbamoyl}-4-hydroxy-butyrate BDBM50124339 CHEMBL174430
CHEMBL15232 Sodium; 2-{1-[3-(7-chloro-quinolin-2-ylmethoxy)-phenyl]-3-[2-(1-methyl-1H-tetrazol-5-yl)-phenyl]-propylsulfanylmethyl}-butyrate BDBM50280713
CHEMBL10812 BDBM50076792 Lithium; (S)-2-({5-[5-(4-chloro-3-fluoro-phenyl)-furan-2-ylmethoxymethyl]-2'-methyl-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyrate
cortisol BDBM13775 US10188667, Example 00023 [3H]cortisol (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one 3H-cortisol HYDROCORTISONE 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
BDBM480131 US10899738, Cpd. No 191 rac-(1S,2R)-2- (cyano(phenyl)(1-((1-(4- (pyridin-4- ylsulfonyl)phenyl)azetidin-3- yl)methyl)piperidin-4- yl)methyl)cyclopentyl butyrate
BDBM480132 US10899738, Cpd. No 192 rac-(1R,2S)-2- (cyano(phenyl)(1-((1-(4- (pyridin-4- ylsulfonyl)phenyl)azetidin-3- yl)methyl)pyridin-4- yl)methyl)cyclopentyl butyrate
BDBM514250 US11053207, Compound 13 The Preparation of (+-) (Z)-N-(3-bromo-4-fluorophenyl)-N′-hydroxy(thio-methyl sulfoxide cyano amine)ethyl)amino)-1,2,5-oxadiazole-3-(2,2-dimethyl) butyrate 
CHEMBL510285 Methyl (R)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2Hpyrimidin-1-yl]-1-phenylethylamino}butyrate BDBM50274926
4-[(S)-(R)-3-[3,4-Dihydroxy-5-(1-hydroxy-ethyl)-tetrahydro-furan-2-yloxy]-2-(2-tetradecyl-hexadecanoylamino)-propionylamino]-4-methylcarbamoyl-butyrate(S)-1-formyl-4-guanidino-butyl-ammonium; CHEMBL305648 BDBM50064882
(R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-enyl butyrate BDBM50033739 CHEMBL8806 Butyric acid (R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydro-naphthalen-2-yl)-4-methyl-pent-3-enyl ester
butyric acid 2-[[4-nitro-7-(propylthio)benzofurazan-5-yl]amino]ethyl ester 2-{[4-nitro-7-(propylthio)-2,1,3-benzoxadiazol-5-yl]amino}ethyl butyrate MLS000584443 BDBM67231 cid_4116022 SMR000207029 butanoic acid 2-[[4-nitro-7-(propylthio)-2,1,3-benzoxadiazol-5-yl]amino]ethyl ester 2-[(4-nitro-7-propylsulfanyl-2,1,3-benzoxadiazol-5-yl)amino]ethyl butanoate
2-[[7-(1H-benzimidazol-2-ylsulfanyl)-4-nitro-2,1,3-benzoxadiazol-5-yl]amino]ethyl butanoate butanoic acid 2-[[7-(1H-benzimidazol-2-ylthio)-4-nitro-2,1,3-benzoxadiazol-5-yl]amino]ethyl ester 2-{[7-(1H-benzimidazol-2-ylthio)-4-nitro-2,1,3-benzoxadiazol-5-yl]amino}ethyl butyrate SMR000207028 MLS000584442 butyric acid 2-[[7-(1H-benzimidazol-2-ylthio)-4-nitro-benzofurazan-5-yl]amino]ethyl ester BDBM68015 cid_12005313
butanoic acid [2-tert-butyl-5-methyl-4-(4-methylphenyl)sulfonyl-3-pyrazolyl] ester SMR000308766 BDBM46946 MLS000730490 butyric acid (2-tert-butyl-5-methyl-4-tosyl-pyrazol-3-yl) ester [2-tert-butyl-5-methyl-4-(4-methylphenyl)sulfonyl-pyrazol-3-yl] butanoate 1-tert-butyl-3-methyl-4-[(4-methylphenyl)sulfonyl]-1H-pyrazol-5-yl butyrate [2-tert-butyl-5-methyl-4-(4-methylphenyl)sulfonylpyrazol-3-yl] butanoate cid_4245855
2-[[7-(1-methylimidazol-2-yl)sulfanyl-4-nitro-2,1,3-benzoxadiazol-5-yl]amino]ethyl butanoate butyric acid 2-[[7-[(1-methylimidazol-2-yl)thio]-4-nitro-benzofurazan-5-yl]amino]ethyl ester SMR000207027 MLS000584441 BDBM33120 butanoic acid 2-[[7-[(1-methyl-2-imidazolyl)thio]-4-nitro-2,1,3-benzoxadiazol-5-yl]amino]ethyl ester 2-({7-[(1-methyl-1H-imidazol-2-yl)thio]-4-nitro-2,1,3-benzoxadiazol-5-yl}amino)ethyl butyrate cid_12005312
cid_12005330 butanoic acid 2-[[7-[(3-methoxy-3-oxopropyl)thio]-4-nitro-2,1,3-benzoxadiazol-5-yl]amino]ethyl ester 2-({7-[(3-methoxy-3-oxopropyl)thio]-4-nitro-2,1,3-benzoxadiazol-5-yl}amino)ethyl butyrate 2-[[7-(3-methoxy-3-oxopropyl)sulfanyl-4-nitro-2,1,3-benzoxadiazol-5-yl]amino]ethyl butanoate 2-[[7-(3-methoxy-3-oxidanylidene-propyl)sulfanyl-4-nitro-2,1,3-benzoxadiazol-5-yl]amino]ethyl butanoate MLS000584445 SMR000207031 BDBM34780 butyric acid 2-[[7-[(3-keto-3-methoxy-propyl)thio]-4-nitro-benzofurazan-5-yl]amino]ethyl ester
- Chen, C; Wu, D; Guo, Z; Xie, Q; Reinhart, GJ; Madan, A; Wen, J; Chen, T; Huang, CQ; Chen, M; Chen, Y; Tucci, FC; Rowbottom, M; Pontillo, J; Zhu, YF; Wade, W; Saunders, J; Bozigian, H; Struthers, RS Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem 51: 7478-85 (2009)
- ChEMBL_70656 The Dissociation Constant for Gamma-amino-N-butyrate transaminase
- ChEBML_68398 Compound was tested for inhibition of Gamma-amino-N-butyrate transaminase
- ChEMBL_70647 Concentration dependent inactivation of Gamma-amino-N-butyrate transaminase
- ChEMBL_70648 Concentration dependent inactivation of gGamma-amino-N-butyrate transaminase
- ChEMBL_70649 Binding affinity against Gamma-amino-N-butyrate transaminase
- ChEMBL_70659 Inhibitory activity against Gamma-amino-N-butyrate transaminase
- ChEMBL_39354 Beta-adrenergic agonistic activity in rat proximal colon in presence of phentolamine (10 uM), desmethylimipramine (0.5 uM) and hydrocortisone (30 uM)
- ChEBML_70657 Apparent dissociation constants for inactivation of Gamma-amino-N-butyrate transaminase
- ChEMBL_70658 Compound was tested for the inhibition of Gamma-amino-N-butyrate transaminase (GABA-AT)
- ChEMBL_70672 Compound was evaluated for the competitive inhibition of of Gamma-amino-N-butyrate transaminase
- ChEMBL_922510 Inhibition of Rattus norvegicus (rat) brain gamma-amino butyrate aminotransferase using gamma-amino butyrate as substrate assessed as decrease in NADPH generation after 30 min by spectrophotometric analysis
- ChEBML_70671 Binding affinity against Gamma-amino-N-butyrate transaminase in pig brain
- ChEMBL_70670 Compound was evaluated for the kinetic constant for the inhibition of Gamma-amino-N-butyrate transaminase
- ChEBML_154778 Dissociation constant (KI) for the Pancreatic cholesterol esterase-catalyzed hydrolysis of 4-nitrophenyl butyrate
- ChEMBL_154778 Dissociation constant (KI) for the Pancreatic cholesterol esterase-catalyzed hydrolysis of 4-nitrophenyl butyrate
- ChEMBL_70660 The compound was tested for the inhibition of Gamma-amino-N-butyrate transaminase from pig brain
- ChEBML_154779 Bimolecular rate constant (ki) for the Pancreatic cholesterol esterase-catalyzed hydrolysis of 4-nitrophenyl butyrate
- ChEBML_70532 Compound was tested for the inhibitory effect against Gamma-amino-N-butyrate transaminase from bacteria
- ChEMBL_154779 Bimolecular rate constant (ki) for the Pancreatic cholesterol esterase-catalyzed hydrolysis of 4-nitrophenyl butyrate
- ChEMBL_1784526 Inhibition of porcine pancreatic lipase using p-nitrophenyl butyrate as substrate after 20 mins
- ChEBML_70653 Compound was tested for inhibitory constant of Gamma-amino-N-butyrate transaminase in pig brain at pH of 6.5
- ChEBML_70673 Compound was tested for the inhibitory effect against Gamma-amino-N-butyrate transaminase from pig brain
- ChEBML_70678 KI for pyridoxal 5'-phosphate (PLP)-dependent Gamma-amino-N-butyrate transaminase at pH 7.4
- ChEMBL_1705930 Binding affinity to porcine pancreatic lipase using p-nitrophenyl butyrate as substrate by dixon plot analysis
- ChEMBL_1636265 Inhibition of recombinant mouse DAGLbeta expressed in HEK293T cell membranes using PNP butyrate as substrate by colorimetric assay
- ChEMBL_1636264 Inhibition of full length recombinant human DAGLalpha expressed in HEK293T cell membranes using PNP butyrate as substrate by colorimetric assay
- ChEMBL_70654 Compound was tested for inhibitory constant of Gamma-amino-N-butyrate transaminase in pig brain at pH of 8.5 and 25 degree C
- ChEMBL_88054 Inhibitory activity against human hormone-sensitive lipase (HSL) expressed in the baculovirus was determined by p-nitrophenyl butyrate (PNPB) assay
- ChEMBL_1655009 Inhibition of porcine cholesterol esterase using para-nitrophenyl butyrate as substrate after 5 mins in presence of sodium taurocholate by spectrophotometric method
- ChEMBL_1990831 Reversible inhibition of wild type human MAGL using 4-methylumbelliferyl butyrate as substrate measured after 5 mins by fluorescence assay
- ChEMBL_1995465 Reversible inhibition of wild type human MAGL using 4-methylumbelliferyl butyrate as substrate measured after 5 mins by fluorescence assay
- ChEMBL_1573073 Inhibition of porcine liver esterase using 4-nitrophenyl butyrate substrate assessed as reduction in p-nitrophenol release measured over 5 mins
- ChEMBL_1757792 Competitive inhibition of equine serum BuChE assessed as enzyme-inhibitor complex using p-nitrophenyl butyrate as substrate by Lineweaver-Burk plot analysis
- ChEMBL_1735716 Inhibition of porcine pancreatic lipase using p-nitrophenyl butyrate as substrate pretreated for 15 mins followed by substrate addition and measured after 60 mins
- ChEMBL_1757788 Mixed-type inhibition of equine serum BuChE assessed as enzyme-inhibitor complex using p-nitrophenyl butyrate as substrate by Lineweaver-Burk plot analysis
- ChEMBL_1757790 Non-competitive inhibition of equine serum BuChE assessed as enzyme-inhibitor complex using p-nitrophenyl butyrate as substrate by Lineweaver-Burk plot analysis
- ChEMBL_1757789 Mixed-type inhibition of equine serum BuChE assessed as enzyme-substrate-inhibitor complex using p-nitrophenyl butyrate as substrate by Lineweaver-Burk plot analysis
- ChEMBL_1757791 Non-competitive inhibition of equine serum BuChE assessed as enzyme-substrate-inhibitor complex using p-nitrophenyl butyrate as substrate by Lineweaver-Burk plot analysis
- ChEMBL_1924051 Inhibition of human C-terminal HA-tagged DAGLalpha expressed in HEK293F cell membrane fractions using PNP butyrate as substrate by colorimetric surrogate substrate assay
- ChEMBL_1575199 Inhibition of porcine pancreatic lipase using p-nitrophenyl butyrate as substrate assessed as formation of p-nitrophenol preincubated for 10 mins followed by substrate addition by spectrophotometric method
- ChEMBL_1705938 Inhibition of porcine pancreatic lipase using p-nitrophenyl butyrate as substrate preincubated for 5 mins followed by substrate addition measured after 5 mins by spectrophotometric analysis
- ChEMBL_1631106 Competitive inhibition of porcine pancreatic lipase 4-nitrophenyl butyrate substrate preincubated for 30 mins followed by substrate addition measured after 5 mins by Dixon plot method
- ChEMBL_1924061 Inhibition of human DAGLalpha expressed in HEK293T cell membrane fractions using PNP butyrate as substrate preincubated for 20 mins followed by substrate addition by colorimetric surrogate substrate assay
- ChEBML_1696835 Inhibition of porcine pancreatic lipase using p-nitrophenyl butyrate as substrate pretreated for 15 mins followed by substrate addition measured after 15 mins in presence of plasma by spectrophotometric method
- ChEMBL_1696835 Inhibition of porcine pancreatic lipase using p-nitrophenyl butyrate as substrate pretreated for 15 mins followed by substrate addition measured after 15 mins in presence of plasma by spectrophotometric method
- ChEMBL_1874961 Inhibition of mouse DAGL-alpha expressed in HEK293T cell membranes pre-incubated for 20 mins before PNP-butyrate substrate addition and measured after 30 mins by surrogate substrate assay
- ChEBML_1631102 Inhibition of porcine pancreatic lipase assessed as reduction in 4-nitrophenol formation from 4-nitrophenyl butyrate substrate preincubated for 30 mins followed by substrate addition measured after 5 mins by spectrophotometer
- ChEMBL_1631102 Inhibition of porcine pancreatic lipase assessed as reduction in 4-nitrophenol formation from 4-nitrophenyl butyrate substrate preincubated for 30 mins followed by substrate addition measured after 5 mins by spectrophotometer
- ChEMBL_1874962 Inhibition of mouse DAGL-alpha expressed in HEK293T cell membranes assessed as inhibition constant pre-incubated for 20 mins before PNP-butyrate substrate addition and measured after 30 mins by surrogate substrate assay
- Inhibition Assay The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type and OCT2-transfected MDCKII cells at 7 concentrations from 0.014 μM to 10 μM.MDCKII cells were maintained in minimal essential medium (MEM) with 1% Pen/Strep, 10% fetal bovine serum, and 0.25 mg/mL hygromycin B in an incubator set at 37° C., 90% humidity and 5% CO2. 24 hours prior to assay, media containing 5 mM sodium butyrate were added to MDCKII cells in flasks, and cells were grown to 80-90% confluence. On assay day, cells were trypsinized and resuspended in Krebs-Henseleit Buffer (KHB), pH 7.4 at 5×106 million cells/mL. Cells were preincubated for 15 min in assay plate before addition of test compound or substrate.
- OCT2 Inhibition Assay The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type and OCT2-transfected MDCKII cells at 7 concentrations from 0.014 μM to 10 μM.MDCKII cells were maintained in minimal essential medium (MEM) with 1% Pen/Strep, 10% fetal bovine serum, and 0.25 mg/mL hygromycin B in an incubator set at 37° C., 90% humidity and 5% CO2. 24 hours prior to assay, media containing 5 mM sodium butyrate were added to MDCKII cells in flasks, and cells were grown to 80-90% confluence. On assay day, cells were trypsinized and resuspended in Krebs-Henseleit Buffer (KHB), pH 7.4 at 5×10 million cells/mL. Cells were preincubated for 15 min in assay plate before addition of test compound or substrate.
- Electrophysiology Assay Block of Kir1.1 (ROMK1) currents was examined by whole cell voltage clamp (Hamill et. al. Pfluegers Archives 391:85-100 (1981)) using the IonWorks.RTM. Quattro automated electrophysiology platform (Molecular Devices, Sunnyvale, Calif.). Chinese hamster ovary cells stably expressing Kir1.1 channels were maintained in T-75 flasks in cell culture media in a humidified 10% CO.sub.2 incubator at 37.degree. C. Prior to an experiment, Kir1.1 expression was induced by overnight incubation with 1 mM sodium butyrate. On the day of the experiment, cells were dissociated with 2.5 ml of Versene.TM. (Invitrogen 15040-066) for approximately 6 minutes at 37.degree. C. and suspended in 10 ml of bath solution containing (in mM): 150 NaCl, 10 KCl, 2.7 CaCl.sub.2, 0.5 MgCl.sub.2, 5 HEPES, pH 7.4. After centrifugation, the cell pellet was resuspended in approximately 4.0 ml of bath solution and placed in the IonWorks.RTM. instrument. The intracellular solution consisted of (in mM): 80 K gluconate, 40 KCl.
- Electrophysiology Assay Block of Kir 1.1 (ROMKl) currents was examined by whole cell voltage clamp (Hamill et. al. Pfluegers Archives 391 : 85- 100 (1981)) using the IonWorks Quattro automated electrophysiology platform (Molecular Devices, Sunnyvale, CA). Chinese hamster ovary cells stably expressing Kirl.l channels were maintained in T-75 flasks in cell culture media in a humidified 10% CO2 incubator at 37 0C. Prior to an experiment, Kirl .l expression was induced by overnight incubation with 1 mM sodium butyrate. On the day of the experiment, cells were dissociated with 2.5 ml of Versene (Invitrogen 15040-066) for approximately 6 min at 37 0C and suspended in 10 ml of bath solution containing (in roM): 150 NaCl, 10 KCl, 2.7 CaCl2, 0.5 MgCl2, 5 HEPES5 pH 7.4. After centrifugation, the cell pellet was resuspended in approximately 4.0 ml of bath solution and placed in the Ion Works instrument. The intracellular solution consisted of (in mM): 80 K gluconate, 40 KCl, 20 KF5 3.2 MgCl2, 3 EGTA, 5 Hepes, pH 7.4.
- Electrophysiology Assay Block of Kir1.1 (ROMK1) currents was examined by whole cell voltage clamp (Hamill et. al. Pfluegers Archives 391:85-100 (1981)) using the IonWorks Quattro automated electrophysiology platform (Molecular Devices, Sunnyvale, Calif.). Chinese hamster ovary cells stably expressing Kir1.1 channels were maintained in T-75 flasks in cell culture media in a humidified 10% CO2 incubator at 37 °C. Prior to an experiment, Kir1.1 expression was induced by overnight incubation with 1 mM sodium butyrate. On the day of the experiment, cells were dissociated with 2.5 ml of Versene (Invitrogen 15040-066) for approximately 6 minutes at 37 °C. and suspended in 10 ml of bath solution containing (in mM): 150 NaCl, 10 KCl, 2.7 CaCl2, 0.5 MgCl2, 5 HEPES, pH 7.4. After centrifugation, the cell pellet was resuspended in approximately 4.0 ml of bath solution and placed in the IonWorks instrument. The intracellular solution consisted of (in mM): 80 K gluconate, 40 KCl, 20 KF, 3.2 MgCl2, 3 EGTA, 5 Hepes, pH 7.
- Electrophysiology Assay Block of Kir1.1 (ROMK1) currents was examined by whole cell voltage clamp (Hamill et. al. Pfluegers Archives 391:85-100 (1981)) using the IonWorks Quattro automated electrophysiology platform (Molecular Devices, Sunnyvale, Calif.). Chinese hamster ovary cells stably expressing Kir1.1 channels were maintained in T-75 flasks in cell culture media in a humidified 10% CO2 incubator at 37 C. Prior to an experiment, Kir1.1 expression was induced by overnight incubation with 1 mM sodium butyrate. On the day of the experiment, cells were dissociated with 2.5 mL of Versene (Invitrogen 15040-066) for approximately 6 min at 37 C. and suspended in 10 mL of bath solution containing (in mM): 150 NaCl, 10 KCl, 2.7 CaCl2, 0.5 MgCl2, 5 HEPES, pH 7.4. After centrifugation, the cell pellet was resuspended in approximately 4.0 mL of bath solution and placed in the IonWorks instrument. The intracellular solution consisted of (in mM): 80 K gluconate, 40 KCl, 20 KF, 3.2 MgCl2, 3 EGTA, 5 Hepes, pH 7.4.
- Electrophysiology Assay Block of Kir1.1 (ROMK1) currents was examined by whole cell voltage clamp (Hamill et. al. Pfluegers Archives 391:85-100 (1981)) using the IonWorks Quattro automated electrophysiology platform (Molecular Devices, Sunnyvale, Calif.). Chinese hamster ovary cells stably expressing Kir1.1 channels were maintained in T-75 flasks in cell culture media in a humidified 10% CO2 incubator at 37° C. Prior to an experiment, Kir1.1 expression was induced by overnight incubation with 1 mM sodium butyrate. On the day of the experiment, cells were dissociated with 2.5 mL of Versene (Invitrogen 15040-066) for approximately 6 min at 37° C. and suspended in 10 mL of bath solution containing (in mM): 150 NaCl, 10 KCl, 2.7 CaCl2, 0.5 MgCl2, 5 HEPES, pH 7.4. After centrifugation, the cell pellet was resuspended in approximately 4.0 mL of bath solution and placed in the IonWorks instrument. The intracellular solution consisted of (in mM): 80 K gluconate, 40 KCl, 20 KF, 3.2 MgCl2, 3 EGTA, 5 Hepes, pH 7.4.
- Electrophysiology Assay Block of Kir1.1 (ROMK1) currents was examined by whole cell voltage clamp (Hamill et. al. Pfluegers Archives 391:85-100 (1981)) using the IonWorks Quattro automated electrophysiology platform (Molecular Devices, Sunnyvale, Calif.). Chinese hamster ovary cells stably expressing Kir1.1 channels were maintained in T-75 flasks in cell culture media in a humidified 10% CO2 incubator at 37° C. Prior to an experiment, Kir1.1 expression was induced by overnight incubation with 1 mM sodium butyrate. On the day of the experiment, cells were dissociated with 2.5 mL of Versene (Invitrogen 15040-066) for approximately 6 min at 37° C. and suspended in 10 mL of bath solution containing (in mM): 150 NaCl, 10 KCl, 2.7 CaCl2, 0.5 MgCl2, 5 HEPES, pH 7.4. After centrifugation, the cell pellet was resuspended in approximately 4.0 mL of bath solution and placed in the IonWorks instrument. The intracellular solution consisted of (in mM): 80 K gluconate, 40 KCl, 20 KF, 3.2 MgCl2, 3 EGTA, 5 Hepes, pH 7.4. Ele
- Electrophysiology Assay Block of Kir1.1 (ROMKI) currents was examined by whole cell voltage clamp (Hamill et. al. Pfluegers Archives 391:85-100 (1981)) using the IonWorks Quattro automated electrophysiology platform (Molecular Devices, Sunnyvale, Calif.). Chinese hamster ovary cells stably expressing Kir1.1 channels were maintained in T-75 flasks in cell culture media in a humidified 10% CO2 incubator at 37° C. Prior to an experiment, Kir1.1 expression was induced by overnight incubation with 1 mM sodium butyrate. On the day of the experiment, cells were dissociated with 2.5 ml of Versene (Invitrogen 15040-066) for approximately 6 min at 37° C. and suspended in 10 ml of bath solution containing (in mM): 150 NaCl, 10 KCl, 2.7 CaCl2, 0.5 MgCl2, 5 HEPES, pH 7.4. After centrifugation, the cell pellet was resuspended in approximately 4.0 ml of bath solution and placed in the IonWorks instrument. The intracellular solution consisted of (in mM): 80 K gluconate, 40 KCl, 20 KF, 3.2 MgCl2, 3 EGTA, 5 Hepes, pH 7.4.
- In Vitro Uptake Transporter Assay To assess the inhibition of the OAT1B1 and OAT1B3 uptake transporters, an in vitro uptake transporter assay from Solvo Biotechnology Inc. was used. Uptake experiments with Test Article (TA) at 0.068, 0.2, 0.62, 1.8, 5.5, 16.7 and 50 uM, were performed on CHO cells stably expressing human SLC transporters OATP1B1 and OATP1B3. Parental cell line CHO-K was used as negative control. Cells (1x105 in 200 ul 1:1 mixture of Dulbecco's Modified Eagle's Medium and Ham's F-12 DMEM (F-12, Lonza, N.J., US) supplemented with 5 mM sodium butyrate) were plated on standard 96-well tissue culture plates and incubated 24 hours before the experiment at 37 C. in an atmosphere of 5% CO2 and 95% air. Before experiments the medium was aspirated by vacuum suction, cells were washed with 2x100 ul of Krebs-Henseleit buffer pH 7.3 (prepared from Sigma chemicals, Sigma-Aldrich, St Louis, Mo.). Uptake experiments were carried out at 37 C. in 50 ul of Krebs-Henseleit buffer.
- Enzyme Assay All rate-based assays were performed in black 384-well polypropylene polymerase chain reaction (PCR) microplates (Abgene) in a total volume of 30 μL. Substrate 4-methylumbelliferyl butyrate (4MU-B; Sigma) and either purified mutant MGL (mut-MGLL 11-313 L179S L186S) or purified wild type MGL (wt-MGLL 6H-11-313) were diluted separately into 20 mM PIPES buffer (pH=7.0), containing 150 mM NaCl and 0.001% Tween 20. Compounds of formula (I) were pre-dispensed (50 nL) into the microplate using a liquid handling dispenser prior to adding 4MU-B (25 μL of 1.2× solution to a final concentration of 10 μM) followed by enzyme (5 μL of a 6× solution to a final concentration of 5 nM) to initiate the reaction. Final compound concentrations ranged from 17 to 0.0003 μM. The fluorescence change due to 4MU-B cleavage was monitored with excitation and emission wavelengths of 335 and 440 nm, respectively, and a bandwidth of 10 nm (Safire2, Tecan) at 37° C. for 5 min.
- Electrophysiology Assay Block of Kir1.1 (ROMK1) currents was examined by whole cell voltage clamp (Hamill et. al. Pfluegers Archives 391:85-100 (1981)) using the IonWorks Quattro automated electrophysiology platform (Molecular Devices, Sunnyvale, Calif.). Chinese hamster ovary cells stably expressing Kir1.1 channels were maintained in T-75 flasks in cell culture media in a humidified 10% CO2 incubator at 37° C. Prior to an experiment, Kir1.1 expression was induced by overnight incubation with 1 mM sodium butyrate. On the day of the experiment, cells were dissociated with 2.5 ml of Versene (Invitrogen 15040-066) for approximately 6 minutes at 37° C. and suspended in 10 ml of bath solution containing (in mM): 150 NaCl, 10 KCl, 2.7 CaCl2, 0.5 MgCl2, 5 HEPES, pH 7.4. After centrifugation, the cell pellet was resuspended in approximately 4.0 ml of bath solution and placed in the IonWorks instrument. The intracellular solution consisted of (in mM): 80 K gluconate, 40 KCl, 20 KF, 3.2 MgCl2, 3 EGTA, 5 Hepes, pH 7.4. Electrical access to the cytoplasm was achieved by perforation in 0.13 mg/ml amphotericin B for 4 minutes. Amphotericin B (Sigma A-4888) was prepared as a 40 mg/ml solution in DMSO.
- Electrophysiology Assay Blocking of Kir1.1 (ROMK1) currents was examined by whole cell voltage clamp (Hamill et. al. Pfluegers Archives 391:85-100 (1981)) using the IonWorks Quattro automated electrophysiology platform (Molecular Devices, Sunnyvale, Calif.). Chinese hamster ovary cells stably expressing Kir1.1 channels were maintained in T-75 flasks in cell culture media in a humidified 10% CO2 incubator at 37° C. Prior to an experiment, Kir1.1 expression was induced by overnight incubation with 1 mM sodium butyrate. On the day of the experiment, cells were dissociated with 2.5 mL of Versene (Invitrogen 15040-066), a non-enzymatic cell dissociation reagent, for approximately 6 min at 37° C. and suspended in 10 mL of bath solution containing (in mM): 150 NaCl, 10 KCl, 2.7 CaCl2, 0.5 MgCl2, and 5 HEPES, at pH 7.4. After centrifugation, the cell pellet was resuspended in approximately 4.0 mL of bath solution and placed in the IonWorks instrument. The intracellular solution consisted of (in mM): 80 K gluconate, 40 KCl, 20 KF, 3.2 MgCl2, 3 EGTA, and 5 Hepes, at pH 7.4. Electrical access to the cytoplasm was achieved by perforation in 0.13 mg/mL amphotericin B for 4 min. Amphotericin B (Sigma A-4888) was prepared as a 40 mg/mL solution in DMSO.
- HepaRG-CAR Cell-Based Assay for Quantitation of Glycolate Oxidase Inhibition A HepaRG human hepatic cell line was transfected for stable overexpression of the constitutive androstane receptor (i.e., HepaRG-CAR cells), as reported by van der Mark et al. (Drug Metab. Dispos., 2017, 45:56-67. Overexpression of CAR in these cells resulted in higher levels of glycolate oxidase (GOX) expression compared to the parental HepaRG cells. HepaRG-CAR cells were plated in a 12-wells plate and incubated for 4 weeks until fully differentiated.To measure cellular glycolate flux, the HepaRG-CAR cells were incubated in Williams medium supplemented with 10% fetal bovine serum (FBS), 5 μg/mL insulin, 50 μM hydrocortisone hemisuccinate, 2 mM glutamine, 5000 U/mL penicillin and 5 mg/mL streptomycin. Test compounds were added to the medium at 0, 0.3, 1, 3 or 10 μM and incubated for 30 minutes, after which 500 μM glycolate was also added. After incubation for 48 hours, 400 μL medium was taken from the culture plate and added to 60 μL 37% HCl.Internal standards (2,2-d2 glycolate, 1,2-13C2 oxalate and 13C2-glyoxylate) and hydroxylamine were added followed by another 30 minute incubation at 80° C. The acids were extracted using ethyl acetate with NaCl. The organic phase was dried under nitrogen and derivatized with N-tert-butyldimethylsilyl-N-methyl trifluoroacetamide (MTBSTFA) for 30 minutes at 80° C. The amounts of glycolate, glyoxylate and oxalate were determined by gas chromatography-mass spectrometry (GC-MS) analysis, using a 25 meter CP-Sil 5 CB low bleed column. A standard curve was used to calculate the concentrations of each acid in the culture medium.
- Inhibition Assay The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type and OCT2-transfected MDCKII cells at 7 concentrations from 0.014 μM to 10 μM.MDCKII cells were maintained in minimal essential medium (MEM) with 1% Pen/Strep, 10% fetal bovine serum, and 0.25 mg/mL hygromycin B in an incubator set at 37° C., 90% humidity and 5% CO2. 24 hours prior to assay, media containing 5 mM sodium butyrate were added to MDCKII cells in flasks, and cells were grown to 80-90% confluence. On assay day, cells were trypsinized and resuspended in Krebs-Henseleit Buffer (KHB), pH 7.4 at 5×106 million cells/mL. Cells were preincubated for 15 min in assay plate before addition of test compound or substrate.Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and incubated for 10 minutes. Assay was initiated with the addition of 0.1 mL of 100 μM 14C-TEA in KHB buffer (20 μM final concentration after mixing). The concentration of TEA is based on the Km. After 10 minutes of incubation, the assay mixture was quenched with addition of 0.5 mL of ice-cold 1×PBS buffer. Samples were then centrifuged at 1000 rpm for 5 min and supernatants were removed. Wash steps were repeated four times with ice-cold PBS. Finally, the cell pellets were lysed with 0.2N NaOH and let sit at room temperature for at least 30 min to ensure complete lysis.
- Electrophysiology Assay Block of Kir1.1 (ROMK1) currents was examined by whole cell voltage clamp (Hamill et. al. Pfluegers Archives 391:85-100 (1981)) using the IonWorks Quattro automated electrophysiology platform (Molecular Devices, Sunnyvale, Calif.). Chinese hamster ovary cells stably expressing Kir1.1 channels were maintained in T-75 flasks in cell culture media in a humidified 10% CO2 incubator at 37° C. Prior to an experiment, Kir1.1 expression was induced by overnight incubation with 1 mM sodium butyrate. On the day of the experiment, cells were dissociated with 2.5 mL of Versene (Invitrogen 15040-066) for approximately 6 min at 37° C. and suspended in 10 mL of bath solution containing (in mM): 150 NaCl, 10 KCl, 2.7 CaCl2, 0.5 MgCl2, 5 HEPES, pH 7.4. After centrifugation, the cell pellet was resuspended in approximately 4.0 mL of bath solution and placed in the IonWorks instrument. The intracellular solution consisted of (in mM): 80 K gluconate, 40 KCl, 20 KF, 3.2 MgCl2, 3 EGTA, 5 Hepes, pH 7.4. Electrical access to the cytoplasm was achieved by perforation in 0.13 mg/mL amphotericin B for 4 min. Amphotericin B (Sigma A-4888) was prepared as a 40 mg/mL solution in DMSO. Voltage protocols and current recordings were performed using the IonWorks HT software/hardware system. Currents were sampled at 1 kHz. No correction for liquid junction potentials was used. The test pulse, consisting of a 100 ms step to 0 mV from a holding potential of −70 mV, followed by a 100 ms voltage ramp from −70 mV to +70 mV, was applied before and after a 6 min compound incubation period. Test compounds were prepared by diluting DMSO stock solutions into the bath solution at 3× the final concentration and placed in the instrument in 96-well polypropylene plates.